WUHN Wuhan General Group (China) Inc.

Wuhan Updates on Hemp and CBD-Based Products Line

Wuhan Updates on Hemp and CBD-Based Products Line

BARCELONA, Spain, March 28, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE --  Wuhan General Group (China), Inc. (OTC: WUHN) (the "Company" and "Wuhan"), announced today that its subsidiary MJ MedTech, Inc. (MJ MedTech) has commenced formulations and prototyping for the Dr. AnnaRx line of hemp and CBD based products.

The products listed below are being developed in Phase 1 and readied for sale for Q2 2019 onward. These products come under the Cosmetics and Food segments.

Cosmetic

  • Day Cream
  • Night Cream
  • Facial Cleanser
  • Facial Exfoliator
  • Anti-Aging
  • Shampoo & Conditioner
  • SPF 50+ Sunblock

Food

  • CBD Olive Oil
  • CBD Salad Dressing
  • Infused Coffee
  • Infused Tea
  • Infused Honey
  • CBD Chocolate

In Phase 2 and 3, the range of products will fall under the Topicals and CAMS (Complementary and Alternative Medicines) segment, respectively. The Company is expected to launch its range of Phase 2 and 3 products to the market in Q4 2019 onward.

Topicals

  • CBD Balms for pain and inflammation
  • CBD Ointments for joint care
  • CBD Creams for mind and mood
  • Soft gels

CAMS

  • Capsules
  • Suppositories
  • CBD Extracts 
  • Antioxidants
  • Immune Booster
  • Multivitamins

More highlights:

  • The Company forecasts revenues for Q2, Q3 and Q4 2019 of the amount of $585,000, $2,047,500 and $5,265,000, respectively.
  • Wuhan management executives will be visiting South Africa in April to ensure operational performance and conduct product testing by Wuhan's Chief Medical Officer against our quality standards. 
  • MJ Medtech will officially relocate the head office to Barcelona, Spain in anticipation of the European launch in 2020 where the Dr. AnnaRx line of hemp and CBD-based products will be sold as well as across South Africa and surrounding countries in more than 1,000 pharmacies in 2019.

Wuhan management believes in the transition to the cannabis industry as a strategic move that will ensure future company growth and shareholder value. We are eager to share our vision and success.

About Wuhan General Group (China), Inc.

Wuhan General Group (China), Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that owns, develops and commercializes a range of CBD-based products. At Wuhan, our mission is to advance CBD-based medicine to the forefront by deploying best practice science and medicine, clinical research and emerging technologies.

For further information contact:

Publicly traded company ()

Website:

Public Relations E-mail:

Forward-Looking Statements:

Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.

Source: Wuhan General Group (China), Inc.

EN
28/03/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Wuhan General Group (China) Inc.

 PRESS RELEASE

CORRECTING and REPLACING – Jeff Robinson, CEO of Wuhan, Provides Key...

CORRECTING and REPLACING – Jeff Robinson, CEO of Wuhan, Provides Key Updates and Outlook in a New Audio Interview with SmallCapVoice.com AUSTIN, Texas, May 22, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by SmallCapVoice.com, Inc. and Wuhan General Group, Inc. (OTC PINK: WUHN), please note that additional content and quotations have become available. The corrected release follows: SmallCapVoice.com, Inc. (SCV) and Wuhan General Group, Inc. (OTC PINK: ) (the "Company" and "Wuhan"), announced today that a new audio interview with the Company is now av...

 PRESS RELEASE

Wuhan to Launch CBD Cosmetics and CBD Infused Coffee in South Africa

Wuhan to Launch CBD Cosmetics and CBD Infused Coffee in South Africa Montreal, Nov. 07, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Wuhan General Group, Inc. (OTC PINK: ) (the "Company" and "Wuhan"), is pleased to announce the following corporate updates: Product Launch The Company is delighted to announce the launching of its premium CBD product lines in the coming weeks. The launch includes the CBD cosmetics line and the CBD coffee line in pharmacies, convenience stores and hotels across South Africa. The products are branded under the trademarks: DrAnnaRx™ and Medspresso™ respec...

 PRESS RELEASE

Wuhan General Group Appoints Distinguished Scientist Dr. Hyder A. Khoj...

Wuhan General Group Appoints Distinguished Scientist Dr. Hyder A. Khoja as Chief Scientific Officer Barcelona, Spain, Aug. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Wuhan General Group, Inc. (OTC PINK: ) (the "Company" and "Wuhan"), is positioning itself to become a major player in the US$166B medical CBD (cannabidiol) space, as well as the promising psilocybin and medicinal mushroom health sector. The company is pleased to announce that Dr. Hyder A. Khoja (“Dr. Khoja”) is joining Wuhan General Group as Chief Scientific Officer. In his role as CSO, Dr. Khoja will oversee the compan...

 PRESS RELEASE

Wuhan Announces Strategic Reorganization for Its Operational Advanceme...

Wuhan Announces Strategic Reorganization for Its Operational Advancement in the Medical Marijuana and Psilocybin Mushroom Therapy Markets BARCELONA, Spain, Aug. 07, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Wuhan General Group, Inc. (OTC PINK:) (the "Company" and "Wuhan"), is pleased to announce a strategic reorganization that will better position the company to capitalize on the rapidly changing Medical Marijuana and Psilocybin Mushroom industries, while more closely aligning the business with the company’s three primary growth strategies: optimizing the value of the core; increasing ...

 PRESS RELEASE

Wuhan Provides Updates on Corporate, Psilocybin and Cannabis Q3 2019 M...

Wuhan Provides Updates on Corporate, Psilocybin and Cannabis Q3 2019 Milestones CAPE TOWN, South Africa, July 02, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Wuhan General Group (China), Inc. () (the "Company" and "Wuhan"), is pleased to share the following statements and coming milestones: Statements The company would like to clarify for all past, current and potential future shareholders that Wuhan General Group is a US-registered corporation and has no dealings with any Chinese parties as it relates to its ongoing business activities. To remove any possible confusion with its...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch